IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Alnylam Pharmaceuticals

CUSIP: 02043QAB3 | TRACE | 143 institutional holders

Quarters

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Institutional Holders — Q3 2026

Union Bancaire Privee, UBP SA364,930,000
0.0% of portfolio›$434
Mackay Shields LLC14,813,000
0.6% of portfolio›$16.0M
AGF Management LTD2,300,000
0.0% of portfolio›$2.5M
Axxion S.A.400,000
0.0% of portfolio›$425.7K
Central Pacific Bank - Trust Division224,000
0.0% of portfolio›$242.1K
Bank of New York Mellon Corp215,000
0.0% of portfolio›$234.6K
Oppenheimer Asset Management Inc.79,000
0.0% of portfolio›$85.4K
Wealth Enhancement Advisory Services, LLC13,000
0.0% of portfolio›$13.7K
Alken Asset Management Ltd2,250
0.0% of portfolio›$2.4K
StyleTurnoverLocationFiled
Union Bancaire Privee, UBP SA
364,930,000$4340.0%GrowthMediumGeneva 1, Switzerland2026-11-04
Mackay Shields LLC
14,813,000$16.0M0.6%Deep ValueLowNew York, NY2026-10-13
AGF Management LTD
2,300,000$2.5M0.0%GrowthHighToronto, Australia2026-11-03
Axxion S.A.
400,000$425.7K0.0%CoreN/AGrevenmacher, Netherlands2026-10-22
Central Pacific Bank - Trust Division
224,000$242.1K0.0%CoreMediumHonolulu, HI2026-10-06
Bank of New York Mellon Corp
215,000$234.6K0.0%CoreLowNew York, NY2026-11-05
Oppenheimer Asset Management Inc.
79,000$85.4K0.0%CoreMediumNew York, NY2026-10-27
Wealth Enhancement Advisory Services, LLC
13,000$13.7K0.0%CoreLowPlymouth, MN2026-10-13
Alken Asset Management Ltd
2,250$2.4K0.0%CoreMediumLondon, United Kingdom2026-10-20